Clinical Trial Update: First in Human Study of a Monoclonal Antibody (SOL-116) Targeting BSSL (Bile Salt-Stimulated Lipase), Single and Multiple Dose Parts [Phase 1]

View source ↗

Summary

First-in-human Phase 1 study of SOL-116, a monoclonal antibody targeting BSSL, in rheumatoid arthritis has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• SOL-116

Snippet

Sponsor: Lipum AB | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED | Results posted: 2026-01-08